Corbus Pharmaceuticals Holdings (CRBP) Income from Continuing Operations (2013 - 2025)
Corbus Pharmaceuticals Holdings (CRBP) recorded quarterly Income from Continuing Operations of 1125000.0 in Q3 2025, up 105.87% quarter-over-quarter from 19152000.0 in Q2 2025, and down 26.08% on a YoY basis from 1522000.0 in Q3 2024.
Corbus Pharmaceuticals Holdings (CRBP) Income from Continuing Operations (2013 - 2025) Analysis & Trends
Corbus Pharmaceuticals Holdings' Income from Continuing Operations history runs 13 years deep, the most recent figure standing at 1125000.0 for Q3 2025.
- In Q3 2025, Income from Continuing Operations fell 26.08% year-over-year to 1125000.0; the TTM figure through Sep 2025 stood at 36022000.0 (down 330.11% YoY), while the FY2024 annual figure was 4439000.0, up 109.07% from the prior year.
- Income from Continuing Operations was 1125000.0 for Q3 2025 at Corbus Pharmaceuticals Holdings, up from 19152000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 1780000.0 in Q4 2024 to a low of 19775000.0 in Q1 2025.
- Historically, Income from Continuing Operations has averaged 9325026.0 across 5 years, with a median of 10468000.0 in 2023.
- The sharpest annual moves came in 2024 and 2025: Income from Continuing Operations surged 116.13% in 2024, then slumped 10562.96% in 2025.
- A 5-year view of Income from Continuing Operations shows it stood at 9998361.0 in 2021, then retreated by 7.99% to 10796820.0 in 2022, then declined by 2.2% to 11034000.0 in 2023, then soared by 116.13% to 1780000.0 in 2024, then plunged by 36.8% to 1125000.0 in 2025.
- The last three Income from Continuing Operations figures came in at 1125000.0 (Q3 2025), 19152000.0 (Q2 2025), and 19775000.0 (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | -3.40 Mn |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | -56.48 Mn |
| 10 | Corbus Pharmaceuticals Holdings | 133.67 Mn | 105.86 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 1.13 Mn |
| Jun 30, 2025 | -19.15 Mn |
| Mar 31, 2025 | -19.78 Mn |
| Dec 31, 2024 | 1.78 Mn |
| Sep 30, 2024 | 1.52 Mn |
| Jun 30, 2024 | 948,000.00 |
| Mar 31, 2024 | 189,000.00 |
| Dec 31, 2023 | -11.03 Mn |
| Sep 30, 2023 | -10.47 Mn |
| Jun 30, 2023 | -9.19 Mn |
| Mar 31, 2023 | -17.30 Mn |
| Dec 31, 2022 | -10.80 Mn |
| Sep 30, 2022 | -8.18 Mn |
| Jun 30, 2022 | -12.34 Mn |
| Mar 31, 2022 | -8.52 Mn |
| Dec 31, 2021 | -10.00 Mn |
| Sep 30, 2021 | -13.88 Mn |
| Jun 30, 2021 | -16.70 Mn |
| Mar 31, 2021 | -15.41 Mn |
| Dec 31, 2020 | -20.81 Mn |